DRALSERP
Clinical safety rating
cautionComprehensive clinical and safety monograph for DRALSERP (DRALSERP).
Depletes monoamines (serotonin, norepinephrine, dopamine) from central and peripheral nerve terminals by binding to and inhibiting the vesicular monoamine transporter 2 (VMAT2), impairing storage and leading to enzymatic degradation.
| Metabolism | Primarily hepatic via CYP2D6, CYP1A2, and CYP3A4; active metabolite: reserpiline. |
| Excretion | Primarily hepatic metabolism to inactive metabolites; less than 1% excreted unchanged in urine; approximately 10% eliminated in feces. |
| Half-life | Terminal elimination half-life is 45 to 50 hours; clinically significant as drug accumulates with repeated dosing, requiring careful titration. |
| Protein binding | Approximately 96% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 200 L/kg; extensive tissue distribution, particularly to adipose tissue. |
| Bioavailability | Oral bioavailability is 50% to 60% due to extensive first-pass metabolism. |
| Onset of Action | Oral: 2 to 4 hours for initial hypotensive effect; maximal effect at 3 to 6 weeks of continuous therapy. |
| Duration of Action | Oral: Hypotensive effect lasts 24 to 48 hours after a single dose; with chronic dosing, effect persists for weeks after discontinuation due to long half-life. |
| Molecular Weight | 446.6 |
0.25 mg orally once daily; may increase by 0.25 mg every 2 weeks to a maximum of 1 mg daily in divided doses.
| Dosage form | TABLET |
| Renal impairment | No specific adjustment required; use with caution in severe renal impairment. |
| Liver impairment | Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), reduce dose by 50%. |
| Pediatric use | Not recommended for use in pediatric patients. |
| Geriatric use | Start at 0.125 mg orally once daily; titrate slowly to avoid excessive sedation and hypotension. |
| 1st trimester | Teratogenic in animal studies; risk of fetal cardiovascular and neural tube defects. Avoid use unless no safer alternative. |
| 2nd trimester | May cause fetal bradycardia and hypoxia. Use only if benefit outweighs risk. |
| 3rd trimester | Risk of uterine atony and postpartum hemorrhage. Avoid near term. |
Clinical note
Comprehensive clinical and safety monograph for DRALSERP (DRALSERP).
| Placental transfer | Crosses placenta; achieves fetal serum concentrations 50-100% of maternal levels. |
| Breastfeeding | Excreted into breast milk in low concentrations; potential for adverse effects (hypotonia, bradycardia) in neonate. Use caution. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | First trimester: Associated with increased risk of congenital malformations including cardiovascular and neural tube defects. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and neonatal hypotension. Avoid throughout pregnancy. |
| Fetal Monitoring | Monitor maternal blood pressure and heart rate; fetal ultrasound for growth and amniotic fluid volume; neonatal monitoring for hypotension and bradycardia after delivery. |
| Fertility Effects | May impair female fertility by disrupting ovulatory function; reversible upon discontinuation. In males, may cause erectile dysfunction and reduced libido. |
■ FDA Black Box Warning
Risk of depression and suicidal ideation; contraindicated in patients with a history of depression, suicidal tendencies, or Parkinson's disease.
| Serious Effects |
Hypersensitivity to rauwolfia alkaloidsActive peptic ulcerUlcerative colitisHistory of depressionConcurrent MAO inhibitor therapy
| Precautions | May cause severe depression, suicidal thoughts, and extrapyramidal symptoms; avoid in patients with history of peptic ulcer disease (increases gastric acid secretion); may cause nasal congestion, bradycardia, and hypotension; use caution during surgery due to increased vagal tone. |
| Food/Dietary | Avoid tyramine-rich foods (aged cheese, cured meats, fermented products, soy sauce, tap beer) as reserpine can potentiate pressor response. Limit caffeine intake. Taking with food may reduce GI upset. |
| Clinical Pearls | DRALSERP (reserpine) is an older antihypertensive that depletes catecholamines. Monitor for depression, especially in elderly. Onset slow (2-3 weeks). Avoid in patients with history of peptic ulcer disease due to increased gastric acid secretion. Combine with thiazide diuretic if necessary but watch for enhanced hypotensive effect. |
| Patient Advice | Take exactly as prescribed, usually once daily. Full effect may take several weeks. · Avoid driving or operating heavy machinery until you know how this medication affects you, as it may cause dizziness or drowsiness. · Report any symptoms of depression, such as persistent sadness, loss of interest, or changes in sleep or appetite. · This drug can cause nasal congestion, dry mouth, or weight gain. Notify your doctor if these are bothersome. · Avoid alcohol, as it may increase side effects like dizziness and drowsiness. · Do not use over-the-counter cold, allergy, or weight loss products without consulting your doctor, as they may interact. |
Loading safety data…